bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
'I've seen firsthand in my practice the need for a noninvasive, accurate and real-time diagnostic for lung cancer. I believe CyPath® Lung is particularly useful in managing indeterminate lung nodules by filling a critical gap in clinical decision-making."
Share
Dr. Downie has authored more than 30 peer-reviewed publications, many centered on innovation in bronchoscopy, early lung cancer diagnosis and medical device development. He has worked extensively in both academic medicine and private practice, led FDA-approved research programs, and served in national leadership roles with the American College of Chest Physicians in the areas of interventional pulmonology, lung cancer, and medical ethics.
'It's a privilege to join bioAffinity at such a pivotal time,' Dr. Downie said. 'I've seen firsthand in my practice the need for a noninvasive, accurate and real-time diagnostic for lung cancer. I believe CyPath® Lung is particularly useful in managing indeterminate lung nodules by filling a critical gap in clinical decision-making. I'm excited by the opportunity to expand access to this innovative technology that can save lives.'
In 2007, Dr. Downie left academia and opened a pulmonology practice in rural East Texas, an underserved area with limited access to healthcare. The lack of pulmonary care is exacerbated by an aging population and rising rates of lung disease, including COPD. Most recently, he was the Director of the Lung Nodule Clinic and Interventional Pulmonology at Titus Regional Medical Center.
Dr. Downie earned his PhD in experimental pathology from the State University of New York at Buffalo (SUNY Buffalo) and his medical degree from Northwestern University. He completed residency and fellowship training at the University of North Carolina at Chapel Hill, and subsequently served on the faculty at SUNY Buffalo and the Brody School of Medicine at East Carolina University.
'Dr. Downie brings a rare blend of clinical excellence, research insight, and innovation in delivery of care,' said Maria Zannes, President and CEO of bioAffinity Technologies. 'His depth of experience in interventional pulmonology and his passion for early cancer detection make him the ideal leader to guide our clinical strategy as we scale CyPath® Lung and expand our diagnostic platform to additional diseases.'
Prior to pursuing his career in medicine, Dr. Downie was an Olympic bronze medalist at the 1976 Summer Olympics in Montreal as part of Great Britain's men's 4×200-meter freestyle relay swim team. He also won silver and bronze medals at the 1975 World Aquatics Championships and was a four-time NCAA All-American swimmer for the University of Michigan.
'It's that same spirit of commitment and discipline that has made Dr. Downie a world-class physician respected by his peers throughout the country,' Ms. Zannes said. 'We are delighted to welcome him to bioAffinity.'
About CyPath® Lung
CyPath ® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit www.cypathlung.com.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding CyPath® Lung's usefulness in managing indeterminate lung nodules by filling a critical gap in clinical decision-making, expanding access to CyPath® Lung technology to save lives, Dr. Downie's contribution to scaling CyPath® Lung, and expanding the Company's diagnostic platform to additional diseases. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to accelerate the commercial growth of CyPath® Lung, Dr. Downie's ability to help expand access to CyPath® Lung technology and guide the Company's clinical strategy, the Company's ability to advance new diagnostics for additional diseases, and the other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a few seconds ago
- Business Wire
Nanoco Reorganizes R&D and Invests in New Technology Resources for Next Chapter of Growth
RUNCORN, England--(BUSINESS WIRE)--Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of quantum dots and other nanomaterials emanating from its technology platform, announces the appointment of a new Director of Technology, alongside new investments in its R&D organization, concurrent with upcoming retirement of its Founder and CTO. Retirement of Dr. Nigel Pickett Dr. Nigel Pickett, Nanoco's founder, CTO and board member, has announced his pending retirement, effective August 19, 2025. Over the next six months, he will focus on long-term technology initiatives and will transition into an advisory role by February 2026. Nigel co-founded Nanoco in 2000 and has worked with the company from a small startup affiliated with University of Manchester, to a recognized leader in Quantum Dot (QD) technology, a vibrant organization with 350 patents making significant contributions to commercial applications of QDs in industries as diverse as Display, Image Sensor, Lighting, and Photovoltaic, among others. Jalal Bagherli, CBE, Nanoco's Chairman of the Board, commented: ' Nigel has made a significant contribution to Nanoco since its founding – the company was his life for the last quarter century. Because of Nigel's resourcefulness and ingenuity, Nanoco is now a leader in its field. We wish Nigel all the best in his well-deserved retirement.' Nanoco's Technology leadership Concurrent with Dr. Pickett's retirement, Nanoco announced several promotions in its R&D organization. Dr. Ombretta Masala, previously serving as Section Head, Nanomaterials, is assuming the role of Director of Technology, reporting to Nanoco's CEO Dmitry Shashkov. Dr. Masala has worked with Nanoco for nearly 20 years. In recognition of his outstanding technical expertise, Dr. James Harris has expanded his current role to become Head of QD Technologies. Dr. Parthiban Ramasamy has been promoted to the position of Lead Scientist, focusing his work on Image Sensor development. Dmitry Shashkov, Nanoco's CEO, commented: 'Under Nigel's leadership, the next generation of technology leaders have grown within the Company who are ready to lead Nanoco's Technology team through our next chapter of growth. With significant experience, Ombretta is the right person for the job. Since the launch of our new strategy in October, Nanoco has formed and strengthened several technical collaborations, all stemming from our strong reputation for QD technology development. I want to congratulate Ombretta, James and Parthiban with their expanded roles.' Investment in additional Technology resources Nanoco also announced several new hires into its R&D organization, further strengthening its technology talent base. Dr. Teoman Taskesen has joined Nanoco as Device Physicist. Teo joins the company after his previous 5-year tenure at Oxford Photovoltaics. Prior to that, he has had a successful international career in both academic and industrial settings related to Semiconductors, Quantum Dots and Photovoltaics (PV) in Turkey, Estonia and Germany. Dr. Rounak Naphade has joined Nanoco as Senior Chemist. Rounak comes to the company from University of Chicago, where for the last two years he worked on Quantum Dot (QD) development for infrared image sensors in the world-renowned lab of Prof. Philippe Guyot-Sionnest. Prior to University of Chicago, Rounak conducted doctoral and post-doctoral QD research in well-known academic centers in Saudi Arabia and India. Dr. Asim Önal has also joined the company as Senior Chemist. Asim comes to Nanoco after completing his PhD in Koc University in Istanbul, where he focused on development of QDs for Lighting, Display, and Biomedical applications. Prior to his PhD, Asim completed more than 5 years of undergraduate and graduate-level QD research in Turkey and Germany. Dr. Ombretta Masala, Nanoco's newly appointed Director of Technology, commented: 'We welcome Teo, Rounak, and Asim to Nanoco. Our growth and our reputation as a company depend on our team. All of our new hires come from distinguished technical backgrounds and bring their unique expertise to the company – we are delighted to expand our technology team with such strong, international talent.' Notes for editors: About Nanoco Group plc Nanoco (LSE: NANO) is a nanomaterial production and licensing group, specialising in the production of its patented cadmium free quantum dots (CFQD® materials) and other patented nanomaterials for use in the electronics industries. Founded in 2001 and headquartered in Runcorn, UK, Nanoco continues to build out a world-class, patent-protected IP portfolio alongside its existing scaled up production facilities for commercial orders. Nanomaterials are materials with dimensions typically in the range 1 - 100 nm. Nanomaterials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nanomaterial that have size-dependent optical and electronic properties. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Sensor, Electronics and Display markets. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of display applications. Nanoco's HEATWAVE® quantum dots can be tuned to absorb light at different wavelengths across the near-infrared spectra, rendering them useful for applications including cameras and image sensors. Nanoco is listed on the Main Market of the London Stock Exchange, holds the LSE's Green Economy Mark, and trades under the ticker symbol NANO. For further information please visit:
Business Wire
a few seconds ago
- Business Wire
Jackson Healthcare Named to PEOPLE Companies That Care List for Second Consecutive Year
ATLANTA--(BUSINESS WIRE)-- Jackson Healthcare ®, one of the nation's premier providers of healthcare workforce services, today announced its second consecutive appearance on the PEOPLE ® Companies that Care list published by PEOPLE and Great Place To Work ®. This distinction highlights and celebrates businesses that lead with care for their people, local communities and the world. 'Being named again to the PEOPLE Companies that Care list is a testament to our deeply rooted company mission and values,' said Shane Jackson, president of Jackson Healthcare. 'One of our core values, Others First, guides us in putting people at the center of everything we do. We prioritize caring for our team and empowering them to make a meaningful impact through their work.' 'This recognition also reflects our deep commitment to providing a hand up in the communities in which we live, work and serve,' added Jackson. 'Through our LoveLifts community impact platform, we partner with over 450 nonprofit organizations worldwide to improve access to healthcare and enhance the wellbeing of young people. This recognition from PEOPLE and Great Place To Work honors the passion and purpose of our people within our organization and beyond, and I could not be more proud.' 'Businesses are vital pillars in the communities where they operate,' stated Michael C. Bush, CEO of Great Place To Work ®. 'Caring for your people and your community isn't something you do after you build a successful business; it's how to make your business successful.' The PEOPLE Companies that Care list is compiled using data from the Great Place To Work Trust Index ™ Survey, which measures whether all employees have a consistently positive experience at work, regardless of background or role. Companies that earn this recognition also submit a narrative with qualitative and quantitative insights to provide a complete picture of how their organizations care for their employees, communities and planet. To be considered for the list, companies must also be Great Place To Work ® Certified ™. 'Witnessing the innovative spirit with which these companies invest in their employees, communities and the world is truly invigorating,' added Charlotte Triggs, PEOPLE GM and editor-in-chief. 'Their commitment reflects our mission, to feature what happens when ordinary people do extraordinary work.' In addition to being on the 2025 PEOPLE Companies that Care list, Jackson Healthcare is on the 2025 Fortune 100 Best Companies to Work For ® list, as well as it's most recent Best Workplaces for Women ™ and Best Workplaces in Health Care ™ lists. The organization has also been Great Place To Work Certified for nearly a decade. About the PEOPLE Companies That Care List Great Place To Work selected the 2025 PEOPLE Companies that Care list by gathering and analyzing over 1.3 million confidential survey responses from companies representing more than 8.4 million U.S. employees at Great Place To Work Certified organizations. Of those, more than 1 million responses came from employees at companies eligible for the list, and these rankings are based on that feedback. Company rankings are derived from 60 employee experience questions within the Great Place To Work Trust Index ™ Survey and essays submitted by participating companies. Read the full methodology. About PEOPLE Launched in 1974, PEOPLE revolutionized personality journalism by celebrating the extraordinary in ordinary people and the ordinary in extraordinary people. Over 50 years later, it remains a trusted authority on human interest and celebrity news, reaching over 100 million consumers through digital platforms, video, social media, the PEOPLE app and print. Renowned for iconic issues such as Sexiest Man Alive and World's Most Beautiful, PEOPLE delivers breaking entertainment news, exclusive red carpet access, and in-depth reporting on today's most compelling newsmakers. With a legacy of award-winning journalism and photojournalism, PEOPLE, a brand of People Inc., is ranked No. 1 in the entertainment news category by Comscore. About Great Place To Work As the global authority on workplace culture, Great Place To Work brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Its proprietary platform and Great Place To Work Model ™ help companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified or receiving recognition on a coveted Best Workplaces ™ List. Follow Great Place To Work on LinkedIn, Twitter, and Instagram, or visit and sign up for the newsletter to learn more. About Jackson Healthcare Jackson Healthcare ® is one of the nation's premier providers of healthcare workforce services and the parent company of more than 20 businesses that share a common mission: to improve the delivery of patient care and the lives of everyone it touches. Powered by expert associates and tens of thousands of clinician providers, it delivers quality care when and where it's needed in communities across the country – helping thousands of health systems, hospitals and medical facilities serve over 20 million patients a year. Jackson Healthcare – which marks its 25 th anniversary in 2025 – is Great Place To Work ® Certified ™ and appears on the latest Forbes list of America's Top Private Companies; Fortune lists of the 100 Best Companies to Work For ® and Best Workplaces in Health Care ™; and PEOPLE ® list of Companies that Care. Learn more at
Forbes
a minute ago
- Forbes
Viking Therapeutics: What's Happening With VKTX Stock?
Viking Therapeutics (NASDAQ: VKTX) fell 42% on August 19, 2025, after Phase 2 results for its oral obesity pill VK2735 disappointed investors. The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli Lilly and Novo Nordisk. Moreover, 28% of patients discontinued therapy due to side effects such as nausea and vomiting. Even so, we think the magnitude of the selloff looks somewhat overdone. We expand on this view in the sections below. If you're seeking upside with less volatility than a single stock, consider the High Quality Portfolio. It has comfortably outperformed its benchmark—a combination of the S&P 500, Russell, and S&P midcap indexes—with returns exceeding 91% since inception. Also, see – Oracle: ORCL Stock To $160? Pipeline Beyond VK2735: Multiple Shots on Goal Despite the setback, Viking still has several promising candidates that the market may be overlooking: Valuation Disconnect At $24 versus the $89 analyst average price target, Viking trades at a steep discount. While some targets will likely be revised lower, the size of the decline appears excessive for a company with no commercial revenue whose value is tied to a diversified pipeline rather than a single program. Of course, we could be wrong, especially if investors were primarily banking on the obesity pill as the core growth driver, in which case the stock could keep sliding despite pipeline breadth. The Verdict Surely, there is always a meaningful risk when investing in a single, or just a handful, of stocks. Consider the Trefis High Quality (HQ) Portfolio, which, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index—less of a roller-coaster ride—as shown in HQ Portfolio performance metrics.
